5‐ASA may leads to lower withdrawal due to adverse events compared with purine antimetabolites (low certainty).
It is very uncertain whether 5‐ASA changes withdrawal due to adverse events compared with no treatment (very low certainty).
5‐ASA showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
Oral 5‐ASA showed no clear difference in withdrawal due to adverse events compared with comparator 5‐ASA (moderate certainty).
5‐ASAs showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
It is very uncertain whether 5‐ASAs changes withdrawal due to adverse events compared with anti TNF‐ɑ (very low certainty).
High dose 5‐ASA showed no clear difference in withdrawal due to adverse events compared with low dose 5‐ASA (low certainty).
Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with SASP (moderate certainty).
Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with placebo (moderate certainty).
The review found no eligible studies for this question.
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes withdrawal due to adverse events (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
It is very uncertain whether probiotics changes withdrawal due to adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawals due to adverse events compared with 5‐ASA or Sulfasalzine (low certainty).
It is very uncertain whether probiotics changes withdrawal due to adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).